Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin.

Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin.
复制标题

DOI:
10.1016/j.canlet.2021.09.020
复制
发表时间:
2021-12-01
期刊:
影响因子:
9.7
通讯作者:
Foster DA
Foster DA
中科院分区:
医学1区
文献类型:
--
作者:
Chakraborty S;Utter MB;Frias MA;Foster DA

文献摘要

参考文献

被引文献

相似文献

在缺乏转化生长因子-β (TGFβ) 信号传导的情况下,用雷帕霉素抑制哺乳动物雷帕霉素靶点复合物 1 (mTORC1) 可诱导许多癌细胞系凋亡。在 TGFβ 存在的情况下,雷帕霉素会诱导 G1 细胞周期停滞;然而,在没有 TGFβ 的情况下,细胞不会停滞在 G1 期并进入 S 期,此时雷帕霉素具有细胞毒性而不是细胞抑制作用。然而,我们观察到DU145前列腺癌细胞和NCI-H2228肺癌细胞对雷帕霉素的细胞毒性作用具有抵抗力。有趣的是,雷帕霉素耐药的 DU145 和 NCI-H2228 细胞的 RB 和 CDKN2A 肿瘤抑制基因发生突变。 RB 和 CDKN2A 的基因产物(pRb 和 p14ARF)抑制 E2F 家族转录因子,促进细胞周期从 G1 进展到 S。DU145 和 NCI-H2228 细胞中野生型 RB 的恢复或 E2F 活性的抑制导致雷帕霉素敏感性。这些数据提供了证据,证明癌细胞中突变型 RB 和突变型 CDKN2A 的组合会导致雷帕霉素耐药性,这对抗癌治疗的精准医学方法具有重要意义。
Inhibition of mammalian target of rapamycin complex 1 (mTORC1) with rapamycin in the absence of transforming growth factor-β (TGFβ) signaling induces apoptosis in many cancer cell lines. In the presence of TGFβ, rapamycin induces G1 cell cycle arrest; however, in the absence of TGFβ, cells do not arrest in G1 and progress into S-phase where rapamycin is cytotoxic rather than cytostatic. However, we observed that DU145 prostate and NCI-H2228 lung cancer cells were resistant to the cytotoxic effect of rapamycin. Of interest, the rapamycin-resistant DU145 and NCI-H2228 cells have mutations in the RB and CDKN2A tumor suppressor genes. The gene products of RB and CDKN2A (pRb and p14ARF) suppress E2F family transcription factors that promote cell cycle progression from G1 into S. Restoration of wild type RB or inhibition of E2F activity in DU145 and NCI-H2228 cells led to rapamycin sensitivity. These data provide evidence that the combination of mutant RB and mutant CDKN2A in cancer cells leads to rapamycin resistance, which has implications for precision medicine approaches to anti-cancer therapies.
DOI: 10.1371/journal.pone.0074157
发表时间: 2013
期刊: PloS one
影响因子: 3.7
作者:
Saqcena M;Menon D;Patel D;Mukhopadhyay S;Chow V;Foster DA
通讯作者: Foster DA
DOI: 10.1158/1535-7163.mct-15-0720
发表时间: 2016-03
影响因子: 5.7
作者:
Mukhopadhyay S;Frias MA;Chatterjee A;Yellen P;Foster DA
通讯作者: Foster DA
DOI: 10.18632/aging.100422
发表时间: 2011-12
期刊: Aging
影响因子: --
作者:
Blagosklonny MV
通讯作者: Blagosklonny MV
DOI: 10.1158/1078-0432.ccr-13-2175
发表时间: 2014-03-15
影响因子: 11.5
作者:
Alhejaily, Abdulmohsen;Day, Andrew G.;LeBrun, David P.
通讯作者: LeBrun, David P.
DOI: 10.1016/j.trecan.2016.03.008
发表时间: 2016-05
期刊: TRENDS IN CANCER
影响因子: 18.4
作者:
Ilagan, Erika;Manning, Brendan D.
通讯作者: Manning, Brendan D.